Abstract 934P
Background
Locally advanced hypopharyngeal carcinoma (LAHC), an aggressive type of head and neck cancer (HNC), generally exhibits poor prognosis. Currently, The programmed death 1 inhibitors, implicated in antitumor activity, emerge as meaningful option in patients with recurrent or metastatic HNC, but the role of camrelizumab remains uncertain. Aim to determine effects and safety of induction therapy of camrelizumab plus TPF (docetaxel, cisplatin, and capecitabine) in LAHC.
Methods
In this single-arm, phase 2, prospective, and single-center trial, patients with T3-4aN0-3M0 LAHC received induction therapy for three cycles: camrelizumab 200 mg on day 1, docetaxel 75 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1-3, capecitabine 800 mg/m2 bid on day 1-14, every three weeks. Patients were assigned to radiotherapy and immunotherapy if they had a complete response or partial response (PR) or assigned to surgery and adjuvant (chemo)radiotherapy if they had stable disease (SD) or progressive disease that was defined by using a tumor volume evaluation system. Camrelizumab was maintained postradiotherapy and immunotherapy for a total of 18 doses. This trial was registered with ClinicalTrials.gov, No. NCT04156698 and is ongoing.
Results
Fifty-one patients were enrolled from May 21, 2020, to April 15, 2023, and the mean duration of follow-up was 16.5 ± 8.7 months. After induction therapy, 42 (82.4%) patients showed PR, and 9 (17.6%) showed SD. Treatment-related adverse events were recorded, leading to treatment suspension in 9 (17.6%) patients but no death. The most common adverse event was alopecia (100%), followed by RCCEP (90.2%), nausea/vomiting (84.3%), and fatigue (58.8%) in the induction therapy period. Twenty-six (51.0%) patients experienced grade 3 or 4 induction therapy-related adverse events. The two-year overall survival, progression-free survival, and laryngeal function preservation rates were 85.5%,72.8%, and 65.4%, respectively.
Conclusions
Camrelizumab plus TPF was well tolerated and demonstrated effective antitumor activity in LAHC, indicating future therapy options of camrelizumab as antitumor MAb for advanced HNC.
Clinical trial identification
NCT04156698.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by the National Natural Science Foundation of China (81502343 and 81972529), Clinical Research Plan of SHDC (SHDC2020CR6011), the Science and Technology Commission of Shanghai Municipality (21Y11900100 and 19411961300).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12